F10 and chronic kidney disease: Patients in the fXa inhibitor group were older (78.4 years fXa inhibitor group vs 73.9 years warfarin group, P = 0.03), while patients in the warfarin group had a higher incidence of end-stage renal disease (2.1% vs 18%, P < 0.01).